VanEck ETF Trust - VanEck Pharmaceutical ETF Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on VanEck ETF Trust - VanEck Pharmaceutical ETF's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Capital Markets Industry Growth | 10.3% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Earnings Update | n/a |
Recent past performance updates
No updates
Recent updates
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
Apr 23PPH: Ignore The Election Scare, Buy Pharma And Healthcare
Jan 19Healthcare outperforms S&P 500 as large cap pharma rebounds
Sep 22PPH Investors Should Keep On Top Of Regulatory Developments
Aug 26PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return
Apr 13In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, VanEck ETF Trust - VanEck Pharmaceutical ETF has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How VanEck ETF Trust - VanEck Pharmaceutical ETF makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|
Quality Earnings: Insufficient data to determine if PPH has high quality earnings.
Growing Profit Margin: Insufficient data to determine if PPH's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if PPH's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare PPH's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if PPH's earnings growth over the past year exceeded the Capital Markets industry average.
Return on Equity
High ROE: PPH has a negative Return on Equity (0%), as it is currently unprofitable.